Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Elevance Health (ELV) and Genmab (GMAB)
A. G. P. Maintains NeuroSense Therapeutics(NRSN.US) With Buy Rating, Maintains Target Price $7.5
NeuroSense Therapeutics Reports Key Progress and Financials
NeuroSense Therapeutics Regains Compliance With Nasdaq Equity Requirement
Express News | Neurosense Regains Compliance With Nasdaq's Minimum Equity Requirement
Neurosense Therapeutics Files for Resale of Up to 5.28 Million Shares
NeuroSense Signs Term Sheet for Phase 3 PrimeC Trial in Amyotrophic Lateral Sclerosis
Express News | Neurosense Therapeutics Ltd: Co Would Retain Full Rights to Primec in Other Key Territories
Express News | Neurosense Therapeutics Enters Binding Term Sheet to Advance Primec for ALS
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
NeuroSense Therapeutics Shares Are Trading Higher. The Stock May Be Moving on a Continued Strength After the Company Reported on Wednesday a Year-over-year Increase in 9-month EPS Results.
Express News | NeuroSense Therapeutics Shares Are Trading Higher. The Stock May Be Moving on a Continued Strength After the Company Reported on Wednesday a Year-over-year Increase in 9-month EPS Results
NeuroSense Therapeutics: Expect to Submit a Dossier in 2Q 2025, With a Regulatory Decision Expected by 1Q 2026 >NRSN
NeuroSense Therapeutics: Estimate Potential Market Opportunity in Canada Is Between $100M to $150M in Peak Annual Rev >NRSN
NeuroSense Therapeutics: Initiated the Regulatory Process to Seek Early Commercialization Approval for PrimeC Under Health Canada >NRSN
NeuroSense Therapeutics: As of Sept 30, 2024, Had Cash of $340,000, Which Does Not Include Gross Proceeds of $5M From Financing Completed in Dec >NRSN
Express News | Neurosense Therapeutics 9M Operating Income USD -8.131 Million
Express News | Neurosense Therapeutics 9M EPS USD -0.48
Press Release: NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
NeuroSense Therapeutics Analyst Ratings